BACKGROUND: The Control to Range Study was a multinational artificial pancreas study designed to assess the time spent in the hypo- and hyperglycemic ranges in adults and adolescents with type 1 diabetes while under closed-loop control. The controller attempted to keep the glucose ranges between 70 and 180 mg/dL. A set of prespecified metrics was used to measure safety. RESEARCH DESIGN AND METHODS: We studied 53 individuals for approximately 22 h each during clinical research center admissions. Plasma glucose level was measured every 15-30 min (YSI clinical laboratory analyzer instrument [YSI, Inc., Yellow Springs, OH]). During the admission, subjects received three mixed meals (1 g of carbohydrate/kg of body weight; 100 g maximum) with meal announcement and automated insulin dosing by the controller. RESULTS: For adults, the mean of subjects' mean glucose levels was 159 mg/dL, and mean percentage of values 71-180 mg/dL was 66% overall (59% daytime and 82% overnight). For adolescents, the mean of subjects' mean glucose levels was 166 mg/dL, and mean percentage of values in range was 62% overall (53% daytime and 82% overnight). Whereas prespecified criteria for safety were satisfied by both groups, they were met at the individual level in adults only for combined daytime/nighttime and for isolated nighttime. Two adults and six adolescents failed to meet the daytime criterion, largely because of postmeal hyperglycemia, and another adolescent failed to meet the nighttime criterion. CONCLUSIONS: The control-to-range system performed as expected: faring better overnight than during the day and performing with variability between patients even after individualization based on patients' prior settings. The system had difficulty preventing postmeal excursions above target range.
BACKGROUND: The Control to Range Study was a multinational artificial pancreas study designed to assess the time spent in the hypo- and hyperglycemic ranges in adults and adolescents with type 1 diabetes while under closed-loop control. The controller attempted to keep the glucose ranges between 70 and 180 mg/dL. A set of prespecified metrics was used to measure safety. RESEARCH DESIGN AND METHODS: We studied 53 individuals for approximately 22 h each during clinical research center admissions. Plasma glucose level was measured every 15-30 min (YSI clinical laboratory analyzer instrument [YSI, Inc., Yellow Springs, OH]). During the admission, subjects received three mixed meals (1 g of carbohydrate/kg of body weight; 100 g maximum) with meal announcement and automated insulin dosing by the controller. RESULTS: For adults, the mean of subjects' mean glucose levels was 159 mg/dL, and mean percentage of values 71-180 mg/dL was 66% overall (59% daytime and 82% overnight). For adolescents, the mean of subjects' mean glucose levels was 166 mg/dL, and mean percentage of values in range was 62% overall (53% daytime and 82% overnight). Whereas prespecified criteria for safety were satisfied by both groups, they were met at the individual level in adults only for combined daytime/nighttime and for isolated nighttime. Two adults and six adolescents failed to meet the daytime criterion, largely because of postmeal hyperglycemia, and another adolescent failed to meet the nighttime criterion. CONCLUSIONS: The control-to-range system performed as expected: faring better overnight than during the day and performing with variability between patients even after individualization based on patients' prior settings. The system had difficulty preventing postmeal excursions above target range.
Authors: Boris Kovatchev; Stephen Patek; Eyal Dassau; Francis J Doyle; Lalo Magni; Giuseppe De Nicolao; Claudio Cobelli Journal: J Diabetes Sci Technol Date: 2009-09-01
Authors: Daniela Elleri; Janet M Allen; Martina Biagioni; Kavita Kumareswaran; Lalantha Leelarathna; Karen Caldwell; Marianna Nodale; Malgorzata E Wilinska; Carlo L Acerini; David B Dunger; Roman Hovorka Journal: Pediatr Diabetes Date: 2012-07-23 Impact factor: 4.866
Authors: Boris Kovatchev; Claudio Cobelli; Eric Renard; Stacey Anderson; Marc Breton; Stephen Patek; William Clarke; Daniela Bruttomesso; Alberto Maran; Silvana Costa; Angelo Avogaro; Chiara Dalla Man; Andrea Facchinetti; Lalo Magni; Giuseppe De Nicolao; Jerome Place; Anne Farret Journal: J Diabetes Sci Technol Date: 2010-11-01
Authors: Firas H El-Khatib; Steven J Russell; David M Nathan; Robert G Sutherlin; Edward R Damiano Journal: Sci Transl Med Date: 2010-04-14 Impact factor: 17.956
Authors: Marc Breton; Anne Farret; Daniela Bruttomesso; Stacey Anderson; Lalo Magni; Stephen Patek; Chiara Dalla Man; Jerome Place; Susan Demartini; Simone Del Favero; Chiara Toffanin; Colleen Hughes-Karvetski; Eyal Dassau; Howard Zisser; Francis J Doyle; Giuseppe De Nicolao; Angelo Avogaro; Claudio Cobelli; Eric Renard; Boris Kovatchev Journal: Diabetes Date: 2012-06-11 Impact factor: 9.461
Authors: Stuart A Weinzimer; Jennifer L Sherr; Eda Cengiz; Grace Kim; Jessica L Ruiz; Lori Carria; Gayane Voskanyan; Anirban Roy; William V Tamborlane Journal: Diabetes Care Date: 2012-07-18 Impact factor: 19.112
Authors: Richard Mauseth; Sandra M Lord; Irl B Hirsch; Robert C Kircher; Don P Matheson; Carla J Greenbaum Journal: J Diabetes Sci Technol Date: 2015-09-14
Authors: Anne H Maas; Yvonne J W Rozendaal; Carola van Pul; Peter A J Hilbers; Ward J Cottaar; Harm R Haak; Natal A W van Riel Journal: J Diabetes Sci Technol Date: 2014-12-18
Authors: Linda A Gonder-Frederick; Jesse H Grabman; Boris Kovatchev; Sue A Brown; Stephen Patek; Ananda Basu; Jordan E Pinsker; Yogish C Kudva; Christian A Wakeman; Eyal Dassau; Claudio Cobelli; Howard C Zisser; Francis J Doyle Journal: J Diabetes Sci Technol Date: 2016-05-03